TABLE 1.
Pulmonary Hypertension | Control Subjects | |||
---|---|---|---|---|
Etiology | Age | 36 ± 19 | ||
IPAH | 5 | Sex | ||
Sarcoid | 1 | M | 2 | |
EtOH | 1 | F | 2 | |
Rheumatic | 1 | |||
Congenital | 1 | Cause of death | Head trauma | |
Drug induced | 1 | |||
IPAH | Non-IPAH | |||
Age | 43 ± 14 | 48 ± 15 | ||
Sex | ||||
M | 2 | 1 | ||
F | 3 | 4 | ||
Echocardiographic, mm Hg | ||||
RVSP | 130 ± 49 | 95 ± 16 | ||
LVEF | >50% | 10–50% | ||
Hemodynamic, mm Hg | ||||
PA mean | 59 ± 17 | 49 ± 10 | ||
PCWP | 7 ± 3 | 18 ± 5 | ||
Six-minute walk, ft | 1010 ± 295 | 1000 ± 95 | ||
Therapy | ||||
Flolan | 2 | 2 | ||
Remodulin | 1 | |||
Flolan, Bosenan | 1 | 1 | ||
Flolan, Sildenafil | 1 | |||
None | 1 | 1 |
Definition of abbreviations: EtOH = ethanol; IPAH = idiopathic pulmonary arterial hypertension; LVEF = left ventricular ejection fraction; PA = pulmonary arterial; PAP = pulmonary arterial pressure; PCWP = pulmonary capillary wedge pressure; RVSP = right ventricular systolic pressure.
Lung tissue samples were examined from four normal control subjects and compared with five patients with PAH and five with other forms of PH.